Sen. Bill Cassidy plots a path for more commercially viable cell and gene therapies

Zachary Brennan

Senior Editor

With the likely approval of a new gene editing therapy coming this week for CRISPR Therapeutics and Vertex, Sen. Bill Cassidy (R-LA) on Tuesday called …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sen. Bill Cassidy plots a path for more commercially viable cell and gene therapies

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sen. Bill Cas­sidy plots a path for more com­mer­cial­ly vi­able cell and gene ther­a­pies

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sen. Bill Cassidy plots a path for more commercially viable cell and gene therapies